Foghorn Therapeutics Inc. (FHTX) stock
FHTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/300% above fair value
$2.05−0.04 (-1.91%)
Close on Nov 12, 2026Market cap $121.74MP/E 29.3Yield –
Foghorn Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Foghorn Therapeutics's enterprise value was $54.63M on Nov 11, 2026, against $179.24M a year earlier. Over the last 5 years it ranged from $54.05M to $809.37M, with a median of $209.79M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $54.63M | -74.7% |
| 2025 | Dec 31, 2025 | $216.00M | +5.5% |
| 2024 | Dec 31, 2024 | $204.72M | +1.4% |
| 2023 | Dec 29, 2023 | $201.99M | +12.8% |
| 2022 | Dec 30, 2022 | $179.08M | -77.9% |
| 2021 | Dec 31, 2021 | $809.37M | +1200.8% |
| 2020 | Dec 31, 2020 | $62.22M | – |
See a number that looks wrong?